Walter Investment Management Corp. (NYSE:WAC) caters to the Financial space. It has a net profit margin of -15.10% and weekly performance is -18.47%. On the last day of trading company shares ended up at $7.46. Walter Investment Management Corp. (NYSE:WAC) distance from 50-day simple moving average (SMA50) is -40.63%.
On 8 February, Walter Investment Management Corp. (NYSE:WAC) announced that David Schneider, EVP of Walter Investment and President, Servicing of Ditech Financial LLC (“Ditech”), will be named President of Ditech with responsibility for leading both the Servicing and Originations businesses, effective immediately. Patricia Cook, EVP of Walter Investment and President, Originations of Ditech, will be leaving the Company.
Galectin Therapeutics, Inc. (NASDAQ:GALT) ended the last trading day at $1.12. Company weekly volatility is calculated as 8.28% and price to cash ratio as 1.51. Galectin Therapeutics, Inc. (NASDAQ:GALT) showed a weekly performance of -12.50%.
Galectin Therapeutics, Inc. (NASDAQ:GALT) said that, it will present source Capital Group’s 2016 Disruptive Growth & Healthcare Conference on February 11, 2016, at 12:00 p.m. Eastern Standard Time.
On 10 February, Everest Re Group Ltd. (NYSE:RE) shares moved down -1.77% and was closed at $184.59. RE EPS growth in last 5 year was 14.40%. Everest Re Group Ltd. (NYSE:RE) year to date (YTD) performance is 0.82%.
On 5 February, Everest Re Group Ltd. (NYSE:RE) reported fourth quarter 2015 after-tax operating income1 available to common shareholders of $353.5 million, or $8.17 per diluted common share, compared to after-tax operating income of $331.5 million, or $7.28 per diluted common share, for the fourth quarter of 2014.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares advanced 5.05% in last trading session and ended the day at $24.33. ENTA has a return on assets of 33.40%. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) quarterly performance is -25.60%.
On February, Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) reported financial results for its fiscal first quarter ended December 31, 2015. Revenue for the three months ended December 31, 2015 was $48.4 million, compared to $77.5 million for the three months ended December 31, 2014.
Omeros Corporation (NASDAQ:OMER) caters to the Healthcare space. Its weekly performance is -8.45%. On the last day of trading company shares ended up at $10.51. Omeros Corporation (NASDAQ:OMER) distance from 50-day simple moving average (SMA50) is 0.38%.
On 30 January, Omeros Corporation (NASDAQ:OMER) provides an overview of the Omeros Corporation ’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Omeros Corporation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.